Prostate Cancer Ontology
Center for Systems Biology, Sichuan University West China Hospital, Sichuan China
跳过导航链接。
折叠 Prostate cancerProstate cancer
展开 Epidemiological aspects of prostate cancerEpidemiological aspects of prostate cancer
展开 Diagnostic aspects of prostate cancerDiagnostic aspects of prostate cancer
折叠 Therapeutic aspects of prostate cancerTherapeutic aspects of prostate cancer
展开 Deferred treatmentDeferred treatment
展开 SurgerySurgery
展开 RadiotherapyRadiotherapy
展开 CryotherapyCryotherapy
折叠 Hormonal therapyHormonal therapy
展开 ChemotherapyChemotherapy
展开 Castration-resistant prostate cancer (CRPC)Castration-resistant prostate cancer (CRPC)
展开 Metastatic prostate cancerMetastatic prostate cancer
展开 Other treatmentOther treatment
Diethylstilboesterol (DES)
Preferred Name Diethylstilboesterol (DES)
Definition Early studies by the Veterans Administration (VACURG) tested oral Diesthylstilboesterol (DES) at 5 mg/day. This dosage was associated with high cardiovascular morbidity and mortality, which was secondary to first-pass hepatic metabolism and the formation of thrombogenic metabolites. Lower doses of 1 mg/day and 3 mg/day were found to be as effective as bilateral orchiectomy, with still more side effects compared to castration.
Synonyms & Abbreviations Diethylstilboesterol (DES)
ReferenceCode NA
ReferenceURL NA
PMID NA
Copyright (C) 2022 Institutes for Systems Genetics, Sichuan University West China Hospital. All Rights Reserved.